Şunu aradınız:: ruxolitinib (İngilizce - Slovence)

jakavi ruxolitinib
jakavi ruksolitinib

jakavi 10 mg tablets ruxolitinib
jakavi 10 mg tablete ruksolitinib

ruxolitinib was not mutagenic or clastogenic.
ruksolitinib ni bil mutagen ali klastogen.

interactions resulting in dose reduction of ruxolitinib
interakcije, zaradi katerih je treba znižati odmerke ruksolitiniba

jakavi contains the active substance ruxolitinib.
zdravilo jakavi vsebuje zdravilno učinkovino ruksolitinib.

effects of ruxolitinib on other medicinal products
vpliv ruksolitiniba na druga zdravila

a causal relationship to ruxolitinib has not been established.
vzročna povezava z ruksolitinibom ni bila dokazana.

each 10 mg jakavi tablet contains 10 mg of ruxolitinib.
ena 10-miligramska tableta jakavi vsebuje 10 mg ruksolitiniba.

haemodialysis is not expected to enhance the elimination of ruxolitinib.
ni pričakovati, da bi hemodializa lahko pospešila izločanje ruksolitiniba iz telesa.

animal studies have shown that ruxolitinib is embryotoxic and foetotoxic.
rezultati raziskav na živalih kažejo, da ruksolitinib deluje toksično na zarodek in plod.

ruxolitinib is eliminated through metabolism catalysed by cyp3a4 and cyp2c9.
ruksolitinib se iz telesa izloča po metabolni poti, ki jo katalizirata cyp3a4 in cyp2c9.

in vitro data indicate that ruxolitinib may inhibit p-gp and bcrp.
po in vitro podatkih ruksolitinib lahko zavira p-glikoprotein in bcrp.

110 patients were randomised to the ruxolitinib arm and 112 patients to the bat arm.
110 bolnikov so randomizirali v skupino z ruksolitinibom, 112 pa v skupino z najboljšim razpoložljivim zdravilom.

mf patients did not become refractory to the pharmacodynamic effects of ruxolitinib treatment over time.
bolniki z mielofibrozo sčasoma niso postali neodzivni na farmakodinamične učinke ruksolitiniba.

it is unknown whether ruxolitinib and/or its metabolites are excreted in human milk.
ni znano, ali se ruksolitinib in/ali njegovi presnovki izločajo v materino mleko.

however, this could be related to the high ruxolitinib dose resulting in pharmacodynamic effects near emax.
po drugi strani pa je za to lahko odgovoren tudi visok odmerek ruksolitiniba, ki je omogočil farmakodinamično učinkovitost blizu maksimalne (emax).

ruxolitinib is mainly metabolised by cyp3a4 (>50%), with additional contribution from cyp2c9.
ruksolitinib se presnavlja zlasti s cyp3a4 (>50 %), del pa prispeva tudi cyp2c9.

a study in healthy subjects indicated that ruxolitinib did not inhibit the metabolism of the oral cyp3a4 substrate midazolam.
v študiji na zdravih osebah ruksolitinib ni zaviral presnove midazolama, peroralnega substrata za cyp3a4.

a whole body autoradiography study in rats has shown that ruxolitinib does not penetrate the blood-brain barrier.
rezultati študije z avtoradiografijo celega telesa na podganah so pokazali, da ruksolitinib ne prehaja krvno- možganske pregrade.

based on studies in healthy subjects, no relevant differences in ruxolitinib pharmacokinetics were observed with regard to gender and race.
po podatkih študij pri zdravih osebah niso opažali pomembnih razlik v farmakokinetičnih lastnostih ruksolitiniba glede na spol ali raso.